S’More, a dating app that’s focused on helping users find more meaningful relationships, announced today that it has raised $2.1 million in seed funding. S’More (short for “som
Most of us are now familiar with apps that track what’s known as our “digital biomarkers.” These include the steps, we’ve taken, our heart rate and our weight. In recent years startups
Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the pharmaceuti
Much of Silicon Valley mythology is centered on the founder-as-hero narrative. But historically, scientific founders leading the charge for bio companies have been far less common.
DNA Script has raised $38.5 million in new financing to commercialize a process that it claims is the first big leap forward in manufacturing genetic material. The revolution in synthetic biology that
As healthcare moves toward genetically tailored treatments, one of the biggest hurdles to truly personalized medicine is the lack of fast, low-cost genetic testing. And few people are more familiar wi
The pace at which the scientific breakthroughs working to bend the machinery of life to the whims of manufacturing have transformed into real businesses has intensified competition in the biomanufactu
Nebula Genomics, the startup that wants to put your whole genome on the blockchain, has announced the raise of $4.3 million in Series A from Khosla Ventures and other leading tech VC’s such as
Fifty-nine startups took the stage at Y Combinator’s Demo Day 2, and among the highlights were a company that helps developers manage in-app subscriptions; a service that lets you create animoji
The blockchain is the buzziest thing on the internet these days and now MIT professor and godfather of the Human Genome Project George Church wants to put your genes on it. His new startup Nebula Geno
Pig organs are the same size as human organs and function pretty much the same way, but pig to human transplantation has long been an elusive goal for researchers due to fear of activating dormant vir
CRISPR, the gene-editing technology revolutionizing the biotech industry, has failed to take home the Nobel prize in chemistry for the second year in a row. Instead, the award went to Jean-Pierre Sauv
Veritas Genetics was one of the first companies to sequence the entire human genome for less than $1,000 in 2015. It’s now taken that technology a step further by delivering the results of you